164 related articles for article (PubMed ID: 36672849)
21. CDKN2B gene expression is affected by 9p21.3 rs10757278 in CAD patients, six months after the MI.
Zivotić I; Djurić T; Stanković A; Milasinovic D; Stankovic G; Dekleva M; Marković Nikolić N; Alavantić D; Zivković M
Clin Biochem; 2019 Nov; 73():70-76. PubMed ID: 31386834
[TBL] [Abstract][Full Text] [Related]
22. Galectin-3 and outcomes after anterior-wall myocardial infarction treated by primary percutaneous coronary intervention.
Di Tano G; Caretta G; De Maria R; Bettari L; Parolini M; Testa S; Pirelli S
Biomark Med; 2018 Jan; 12(1):21-26. PubMed ID: 29243525
[TBL] [Abstract][Full Text] [Related]
23. Galectin-3 and sST2 in prediction of left ventricular ejection fraction after myocardial infarction.
van der Velde AR; Lexis CP; Meijers WC; van der Horst IC; Lipsic E; Dokter MM; van Veldhuisen DJ; van der Harst P; de Boer RA
Clin Chim Acta; 2016 Jan; 452():50-7. PubMed ID: 26528636
[TBL] [Abstract][Full Text] [Related]
24. THE ROLE OF NEUROHORMONAL FACTORS IN THE FORMATION OF A PATIENT'S CLINICAL PROFILE AND THE IMPACT ON STRUCTURAL CARDIAC AND VASCULAR REMODELING IN PATIENTS WITH MYOCARDIAL INFARCTION AFTER REPERFUSION THERAPY.
Vatseba MO; Haliuk NM; Merhel TV; Nesterak RV; Yusypchuk UV
Wiad Lek; 2023; 76(10):2308-2312. PubMed ID: 37948731
[TBL] [Abstract][Full Text] [Related]
25. Proteomic identification of galectin-11 and 14 ligands from
Sakthivel D; Swan J; Preston S; Shakif-Azam MD; Faou P; Jiao Y; Downs R; Rajapaksha H; Gasser R; Piedrafita D; Beddoe T
PeerJ; 2018; 6():e4510. PubMed ID: 29576976
[No Abstract] [Full Text] [Related]
26. Galectin-3 increase in endurance athletes.
Hättasch R; Spethmann S; de Boer RA; Ruifrok WP; Schattke S; Wagner M; Schroeckh S; Durmus T; Schimke I; Sanad W; Baumann G; Borges AC; Knebel F
Eur J Prev Cardiol; 2014 Oct; 21(10):1192-9. PubMed ID: 23723328
[TBL] [Abstract][Full Text] [Related]
27. Epistatic interaction between haplotypes of the ghrelin ligand and receptor genes influence susceptibility to myocardial infarction and coronary artery disease.
Baessler A; Fischer M; Mayer B; Koehler M; Wiedmann S; Stark K; Doering A; Erdmann J; Riegger G; Schunkert H; Kwitek AE; Hengstenberg C
Hum Mol Genet; 2007 Apr; 16(8):887-99. PubMed ID: 17324965
[TBL] [Abstract][Full Text] [Related]
28. The Therapeutic Potential of Blocking Galectin-3 Expression in Acute Myocardial Infarction and Mitigating Inflammation of Infarct Region: A Clinical Outcome-Based Translational Study.
Mosleh W; Chaudhari MR; Sonkawade S; Mahajan S; Khalil C; Frodey K; Shah T; Dahal S; Karki R; Katkar R; Blankesteijn WM; Page B; Pokharel S; Kim M; Sharma UC
Biomark Insights; 2018; 13():1177271918771969. PubMed ID: 29769800
[TBL] [Abstract][Full Text] [Related]
29. Myocardial and Serum Galectin-3 Expression Dynamics Marks Post-Myocardial Infarction Cardiac Remodelling.
Sharma UC; Mosleh W; Chaudhari MR; Katkar R; Weil B; Evelo C; Cimato TR; Pokharel S; Blankesteijn WM; Suzuki G
Heart Lung Circ; 2017 Jul; 26(7):736-745. PubMed ID: 28094123
[TBL] [Abstract][Full Text] [Related]
30. Lymphotoxin-alpha and galectin-2 SNPs are not associated with myocardial infarction in two different German populations.
Sedlacek K; Neureuther K; Mueller JC; Stark K; Fischer M; Baessler A; Reinhard W; Broeckel U; Lieb W; Erdmann J; Schunkert H; Riegger G; Illig T; Meitinger T; Hengstenberg C
J Mol Med (Berl); 2007 Sep; 85(9):997-1004. PubMed ID: 17497114
[TBL] [Abstract][Full Text] [Related]
31. The association between galectin-3 and clinical parameters in patients with first acute myocardial infarction treated with primary percutaneous coronary angioplasty.
Szadkowska I; Wlazeł RN; Migała M; Szadkowski K; Zielińska M; Paradowski M; Pawlicki L
Cardiol J; 2013; 20(6):577-82. PubMed ID: 24338533
[TBL] [Abstract][Full Text] [Related]
32. Galectin-3 Levels and Outcomes After Myocardial Infarction: A Population-Based Study.
Asleh R; Enriquez-Sarano M; Jaffe AS; Manemann SM; Weston SA; Jiang R; Roger VL
J Am Coll Cardiol; 2019 May; 73(18):2286-2295. PubMed ID: 31072572
[TBL] [Abstract][Full Text] [Related]
33. Ticagrelor attenuates myocardial ischaemia-reperfusion injury possibly through downregulating galectin-3 expression in the infarct area of rats.
Liu X; Gu Y; Liu Y; Zhang M; Wang Y; Hu L
Br J Clin Pharmacol; 2018 Jun; 84(6):1180-1186. PubMed ID: 29381821
[TBL] [Abstract][Full Text] [Related]
34. Galectin-1 in early acute myocardial infarction.
Al-Salam S; Hashmi S
PLoS One; 2014; 9(1):e86994. PubMed ID: 24498007
[TBL] [Abstract][Full Text] [Related]
35. Galectin 3: association to neurohumoral activity, echocardiographic parameters and renal function in outpatients with heart failure.
Stoltze Gaborit F; Bosselmann H; Kistorp C; Iversen K; Kumler T; Gustafsson F; Goetze JP; Sölétormos G; Tønder N; Schou M
BMC Cardiovasc Disord; 2016 May; 16():117. PubMed ID: 27246703
[TBL] [Abstract][Full Text] [Related]
36. Two chromosome 9p21 haplotype blocks distinguish between coronary artery disease and myocardial infarction risk.
Fan M; Dandona S; McPherson R; Allayee H; Hazen SL; Wells GA; Roberts R; Stewart AF
Circ Cardiovasc Genet; 2013 Aug; 6(4):372-80. PubMed ID: 23729007
[TBL] [Abstract][Full Text] [Related]
37. Cholesteryl ester transfer protein (CETP) genetic variation and early onset of non-fatal myocardial infarction.
Meiner V; Friedlander Y; Milo H; Sharon N; Ben-Avi L; Shpitzen S; Leitersdorf E; Siscovick DS; Schwartz SM
Ann Hum Genet; 2008 Nov; 72(Pt 6):732-41. PubMed ID: 18637884
[TBL] [Abstract][Full Text] [Related]
38. The association between fibrinogen haplotypes and myocardial infarction in men is partly mediated through pleiotropic effects on the serum IL-6 concentration.
Mannila MN; Eriksson P; Leander K; Wiman B; de Faire U; Hamsten A; Silveira A
J Intern Med; 2007 Feb; 261(2):138-47. PubMed ID: 17241179
[TBL] [Abstract][Full Text] [Related]
39. Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure after ST-Segment Elevation Myocardial Infarction.
Tymińska A; Kapłon-Cieślicka A; Ozierański K; Budnik M; Wancerz A; Sypień P; Peller M; Balsam P; Opolski G; Filipiak KJ
Dis Markers; 2019; 2019():9529053. PubMed ID: 31687050
[TBL] [Abstract][Full Text] [Related]
40. Osteopontin and galectin-3 predict the risk of ventricular tachycardia and fibrillation in heart failure patients with implantable defibrillators.
Francia P; Adduci C; Semprini L; Borro M; Ricotta A; Sensini I; Santini D; Caprinozzi M; Balla C; Simmaco M; Volpe M
J Cardiovasc Electrophysiol; 2014 Jun; 25(6):609-16. PubMed ID: 24400815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
